Intervention Review

You have free access to this content

Trifluoperazine versus placebo for schizophrenia

  1. Kai Koch1,*,
  2. Kamel Mansi2,
  3. Euan Haynes2,
  4. Clive E Adams2,
  5. Stephanie Sampson2,
  6. Vivek A Furtado3

Editorial Group: Cochrane Schizophrenia Group

Published Online: 11 JAN 2014

Assessed as up-to-date: 9 JAN 2013

DOI: 10.1002/14651858.CD010226.pub2


How to Cite

Koch K, Mansi K, Haynes E, Adams CE, Sampson S, Furtado VA. Trifluoperazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010226. DOI: 10.1002/14651858.CD010226.pub2.

Author Information

  1. 1

    The University of Nottingham, School of Medicine, Nottingham, Nottinghamshire, UK

  2. 2

    The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

  3. 3

    Institute of Mental Health, Forensic Psychiatry, Nottingham, Nottinghamshire, UK

*Kai Koch, School of Medicine, The University of Nottingham, University Park, Queens Medical Centre, Nottingham, Nottinghamshire, UK. mzydkuk@nottingham.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 11 JAN 2014

SEARCH

  1. You have free access to this content

    Current Version

    Trifluoperazine versus placebo for schizophrenia

    Kai Koch, Kamel Mansi, Euan Haynes, Clive E Adams, Stephanie Sampson and Vivek A Furtado

    Version of Record online: 11 JAN 2014 | DOI: 10.1002/14651858.CD010226.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Trifluoperazine versus placebo for schizophrenia

    Kai Koch, Kamel Mansi, Euan Haynes and Clive E Adams

    Version of Record online: 14 NOV 2012 | DOI: 10.1002/14651858.CD010226